Lilly to start testing experimental treatment for COVID-19 in nursing homes
The Indianapolis-based drugmaker said it will enroll about 2,400 residents and staff of nursing homes to test an antibody it is developing with a Canadian biotech. Nursing homes account for about 40% of U.S. deaths from COVID-19.